clinical immunology News
-
ROXALL-Group on the EAACI 2019
With a rising tendency and more than 150 million currently affected individuals in Europe the subject of allergy is more present than ever before. This was reflected by the huge amount of international professional visitors of this year’s annual EAACI 2019 (congress of the European Academy of Allergy and Clinical immunology) taking place in Portugal’s capital and harbor city ...
-
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
GAITHERSBURG, Md., Dec. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced preliminary Phase 1/2 results from an ongoing study of NEXI-002, a patient-derived multi-antigen-specific ...
-
SetPoint Medical Receives IDE Approval for U.S. Pivotal Trial to Study its Bioelectronic Platform in Rheumatoid Arthritis Patients
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to study its proprietary bioelectronic platform in patients with rheumatoid arthritis (RA). The multicenter, double-blind, randomized, sham ...
-
Spreading the love this February!
February is no longer just about Valentine’s day, it’s a whole month dedicated to appreciation, wellness, loyalty and spreading the love… not just in a romantic way! Why shouldn’t we celebrate February in the science world? As pioneers of products that assist in ground-breaking discoveries in science and clinical care, we have a strong network of academic and industry ...
By Baker
-
Phthalates heighten risk for childhood asthma
Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to demonstrate an association between childhood asthma and prenatal exposure to two phthalates used in a diverse array of household products. Results appear online in the journal Environmental Health Perspectives. Children born to mothers exposed during pregnancy to higher ...
-
The Lancet Rheumatology publishes clinical trial data demonstrating promising safety and efficacy profile for a Novel Bioelectronic Device in patients with drug refractory rheumatoid arthritis
Device reduced disease activity in 50% of patients who had failed multiple drug classes including Janus Kinase Inhibitors (JAKi) SetPoint Medical, Inc. today announced that data from a first-in-human pilot trial that evaluated its proprietary Vagus Nerve Stimulation (VNS) microregulator in a cohort of patients with multi-drug refractory rheumatoid arthritis (RA) were published in The Lancet ...
-
The Lancet Rheumatology Publishes Clinical Trial Data Demonstrating Promising Safety and Efficacy Profile for a Novel Bioelectronic Device in patients with Drug Refractory Rheumatoid Arthritis
Device reduced disease activity in 50% of patients who had failed multiple drug classes including Janus Kinase Inhibitors (JAKi) SetPoint Medical, Inc. today announced that data from a first-in-human pilot trial that evaluated its proprietary Vagus Nerve Stimulation (VNS) microregulator in a cohort of patients with multi-drug refractory rheumatoid arthritis (RA) were published in The Lancet ...
-
Children, males and blacks are at increased risk for food allergies
A new study estimates that 2.5 percent of the United States population, or about 7.6 million Americans, have food allergies. Food allergy rates were found to be higher for children, non-Hispanic blacks, and males, according to the researchers. The odds of male black children having food allergies were 4.4 times higher than others in the general population. The research, which was funded by the ...
-
Immunai Launches to Fully Map the Entire Immune System to Better Develop Immunotherapies and Cell Therapies
Today, Immunai launches out of stealth to map the entire immune system for better detection, diagnosis, and treatment of disease. Leveraging single-cell technologies and machine learning algorithms, Immunai has mapped out millions of immune cells and their functions, building the largest proprietary data set in the world for clinical immunological data. The company is also announcing $20M in seed ...
By Immunai
-
NIH study shows 32 million Americans have autoantibodies that target their own tissues
More than 32 million people in the United States have autoantibodies, which are proteins made by the immune system that target the body’s tissues and define a condition known as autoimmunity, a study shows. The first nationally representative sample looking at the prevalence of the most common type of autoantibody, known as antinuclear antibodies (ANA), found that the frequency of ANA is ...
-
World Asthma Day: NIH research advances help people with asthma
Today, the National Institutes of Health joins with public health officials, health organizations, and patient groups around the world to recognize World Asthma Day. As NIH's leading supporters of asthma research, we at the National Institute of Environmental Health Sciences (NIEHS), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious ...
-
World Asthma Day: NIH research advances help people with asthma
Statement of Linda S. Birnbaum, Ph.D., director, National Institute of Environmental Health Sciences and National Toxicology Program; Susan B. Shurin, M.D., acting director, National Heart, Lung, and Blood Institute; and Anthony S. Fauci, M.D., director, National Institute of Allergy and Infectious Diseases Today, the National Institutes of Health joins with public health officials, health ...
-
Deep Genomics Appoints Veteran Ferdinand Massari as Chief Medical Officer
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that Ferdinand Massari, M.D., has been appointed Chief Medical Officer. Dr. Massari is based in Boston and will oversee clinical development and contribute to expanding the company’s AI platform and therapeutic portfolio. “In a short period of time, our artificial intelligence platform has ...
-
Amerigo Scientific Introduces the Launch of Polystreptavidin 350
Amerigo Scientific, a distribution company focused on providing critical products and services to the biomedical and life science research communities, now introduces Polystreptavidin 350 for applications in lateral flow, ELISA or CLIA. Diagnosis is a key enabler of universal health coverage and the first line of defense against the spread of many diseases. From rapid treatment and combating ...
-
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimicsTM vaccine, EO2463, in non-Hodgkin lymphoma
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut ...
By Enterome
-
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
TG4050 induced robust anti-tumor cellular immune responses against multiple neoantigen targets in all evaluable patients (4/4). TG4050 monotherapy was also associated with the first signs of clinical activity. TG4050 was well tolerated, with no related Serious Adverse Events reported across the two studies to date. Additional patients are being enrolled, with the aim to treat up to 43 ...
-
Data Driven: Immunai Adds Biocuration, European Hubs with Nebion Acquisition
Immunai has taken some important steps toward its quest to map the entire immune system by completing its second acquisition this year and bolstering its management and board with new executive and entrepreneurial expertise. Immunai has acquired the Swiss-based biocuration and data integration company Nebion for an undisclosed sum. The deal should extend Immunai’s target discovery and drug ...
By Immunai
-
Ariana announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi
Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered into an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies. The ATRACTion project will generate clinical, multi-omic (single cell RNA ...
-
Regor announces the first patient dosed in the U.S. in the Phase II clinical trial for RGT-075, a novel small molecule GLP-1R agonist
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase II clinical trial of the Company’s novel oral small molecule GLP-1 receptor agonist RGT-075 in the U.S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a well-characterized class of hypoglycemic ...
-
Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase I clinical trial of the Company’s next generation targeted inhibitor RGT-419B for the treatment of breast cancer. RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you